"Having treatment options remains critical for us to continue to meet the needs of our patients," Schwartzman said in a press release. "The approval of Simponi Aria offers rheumatologists a new anti-TNF infusible treatment for patients who demonstrate an inadequate response to methotrexate," said Sergio Schwartzman, MD, of Weill Cornell Medical College in New York, who was not involved in GO-FURTHER. In people with certain inflammatory conditions, like AS, there is an excess of TNF-alpha, which leads to joint pain and stiffness. TNF is a protein, called a cytokine, that is naturally produced by the body’s immune system. The US Food and Drug Administration recently approved Simponi Aria (golimumab) for the treatment of adult patients with active psoriatic arthritis (PsA) or. Golimumab, a fully human monoclonal antibody, was previously approved as a once-monthly subcutaneous treatment for moderate-to-severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis. Simponi and Simponi Aria are monoclonal antibodies that are TNF-alpha inhibitors. That ACR20 response occurred rapidly, with significant improvements being seen by week two - after only one infusion - in one-third of patients receiving the active treatment compared with 12% of patients in the placebo group.
0 kommentar(er)
